{
    "clinical_study": {
        "@rank": "53642", 
        "acronym": "SARILNIUSATURN", 
        "arm_group": [
            {
                "arm_group_label": "Sarilumab (SAR153191/REGN88)", 
                "arm_group_type": "Experimental", 
                "description": "One subcutaneous injection every 14 days up to 50 weeks.\nPrednisone or equivalent steroid (as single therapy or in combination with methotrexate/folic acid) are continued as background therapy."
            }, 
            {
                "arm_group_label": "Sarilumab (SAR153191/REGN88) Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One subcutaneous injection every 14 days up to 50 weeks.\nPrednisone or equivalent steroid (as single therapy or in combination with methotrexate/folic acid) are continued as background therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate the efficacy of sarilumab at week 16 in patients with non-infectious uveitis\n      (NIU).\n\n      Secondary Objectives:\n\n        -  To evaluate the change in best corrected visual acuity (BCVA).\n\n        -  To evaluate the safety of subcutaneous sarilumab in patients with NIU.\n\n        -  To evaluate the change in other signs of ocular inflammation."
        }, 
        "brief_title": "Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Uveitis", 
        "condition_browse": {
            "mesh_term": [
                "Uveitis", 
                "Chorioretinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The total duration per patient is up to 58 weeks, which includes a 2 week screening period,\n      16 weeks principal treatment period, 34 weeks extension treatment period (or open label\n      treatment period), and 6 weeks after last treatment administration.\n\n      Non-responder patients, observed within the first 16 weeks, will be offered to be treated by\n      open-label sarilumab.  Patients will be treated for 34 extra weeks (up to 18 extra\n      injections)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  \u226518 years of age.\n\n          -  Non-infectious intermediate-, posterior-, or pan-uveitis in the study eye.\n\n          -  Active disease at screening or evidence of activity within the 3 months prior to\n             screening visit.\n\n          -  On stable dose of prednisone or equivalent steroid compound for at least 4 weeks\n             prior to randomization.\n\n          -  Signed written informed consent.\n\n        Exclusion criteria:\n\n          -  Patient with best-corrected visual acuity worse than 20 ETDRS letters in at least one\n             eye.\n\n          -  Patient with confirmed or suspected uveitis of infectious etiology or uveitis of\n             traumatic etiology.\n\n          -  Patient with primary diagnosis of anterior uveitis.\n\n          -  Prior treatment with anti-IL-6 or IL-6R antagonist therapies, including tocilizumab\n             and sarilumab.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900431", 
            "org_study_id": "ACT13480", 
            "secondary_id": [
                "2012-004845-34", 
                "U1111-1130-6500"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Sarilumab (SAR153191/REGN88)", 
                "description": "Pharmaceutical form:Prefilled syringes Route of administration: subcuteneous", 
                "intervention_name": "Sarilumab SAR153191/REGN88", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarilumab (SAR153191/REGN88)", 
                    "Sarilumab (SAR153191/REGN88) Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarilumab (SAR153191/REGN88)", 
                    "Sarilumab (SAR153191/REGN88) Placebo"
                ], 
                "description": "Pharmaceutical form:solution Route of administration: intravenous", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarilumab (SAR153191/REGN88)", 
                    "Sarilumab (SAR153191/REGN88) Placebo"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "Folic/folinic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sarilumab (SAR153191/REGN88) Placebo", 
                "description": "Pharmaceutical form:Prefilled syringes Route of administration: subcutaneous", 
                "intervention_name": "Sarilumab (SAR153191/REGN88) placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin", 
                "Methotrexate", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02129"
                    }, 
                    "name": "Investigational Site Number 840011"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01608"
                    }, 
                    "name": "Investigational Site Number 840008"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68198-5540"
                    }, 
                    "name": "Investigational Site Number 840009"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slingerlands", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12159"
                    }, 
                    "name": "Investigational Site Number 840005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76012"
                    }, 
                    "name": "Investigational Site Number 840006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "62500"
                    }, 
                    "name": "Investigational Site Number 203001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 2", 
                        "country": "Czech Republic", 
                        "zip": "12808"
                    }, 
                    "name": "Investigational Site Number 203002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75571"
                    }, 
                    "name": "Investigational Site Number 250002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75013"
                    }, 
                    "name": "Investigational Site Number 250001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20132"
                    }, 
                    "name": "Investigational Site Number 380001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "Investigational Site Number 380003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Emilia", 
                        "country": "Italy", 
                        "zip": "42100"
                    }, 
                    "name": "Investigational Site Number 380004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08907"
                    }, 
                    "name": "Investigational Site Number 724001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08028"
                    }, 
                    "name": "Investigational Site Number 724003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Investigational Site Number 724006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "1005"
                    }, 
                    "name": "Investigational Site Number 756001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }, 
                    "name": "Investigational Site Number 792001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }, 
                    "name": "Investigational Site Number 792005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34098"
                    }, 
                    "name": "Investigational Site Number 792003"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Czech Republic", 
                "France", 
                "Italy", 
                "Spain", 
                "Switzerland", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with at least 2-step reduction in Vitreous Haze OR dose of prednisone < 10 mg/day", 
            "safety_issue": "No", 
            "time_frame": "At 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900431"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with anterior chamber score = 0 or at least 2-step reduction in score (Tyndall and flare according to the SUN classification)", 
                "safety_issue": "No", 
                "time_frame": "At 16 weeks"
            }, 
            {
                "measure": "Mean change from baseline in BCVA (ETDRS letters score)", 
                "safety_issue": "No", 
                "time_frame": "At 16 weeks"
            }, 
            {
                "measure": "Number of patients experiencing adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}